This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Puetz, J. J. Articles by Bouhasin, J. D. Search for Related Content PubMed PubMed Citation Articles by Puetz, J. J. Articles by Bouhasin, J. D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Palliative Care Social Bookmarking                         What's this?

Use of recombinant factor VIIa to control bleeding in an adolescent male with severe hemophilia A, HIV, thrombocytopenia, hepatitis C, and end-stage liver disease

St. Louis Hemophilia/Aids Treatment Center, Division of Pediatric Hemostasis and Thrombosis, Cardinal Glennon Children’s Hospital, St. Louis University Health Sciences Center, St. Louis, Missouri

John D. Bouhasin, MD

St. Louis Hemophilia/Aids Treatment Center, Division of Pediatric Hemostasis and Thrombosis, Cardinal Glennon Children’s Hospital, St. Louis University Health Sciences Center, St. Louis, Missouri

Few options are available to treat hemorrhaging during the palliative care of patients. Blood products, such as plasma and platelets, are difficult to transfuse in the home or hospice setting. What is needed is a product that can be given in the home setting for effective control of hemorrhaging in patients with various types of coagulopathies. Unfortunately, no such product currently exists. One agent that may be beneficial in this clinical setting is recombinant factor VIIa. This factor was approved initially for controlling hemorrhaging in patients with hemophilia who have developed antibodies against factor VIII, known as inhibitors. It subsequently has been found to control bleeding in several other clinical situations. We will describe our use of this agent during the palliative care of a patient with numerous insults to his coagulation system.

Key Words: hemophilia • AIDS • recombinant factor VIIa • hemorrhage • hepatitis C • thrombocytopenia • palliation

American Journal of Hospice and Palliative Medicine®, Vol. 19, No. 4, 277-282 (2002)
DOI: 10.1177/104990910201900413


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?